Physician profile
Oneib U Khan
NPI 1912404054
$12,526.84
in general payments reported to CMS, 2019-2025
17 companies · $7,750 in 2025
The $7,750 reported for 2025 was more than what 94% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $51.56 · 2020: $160 · 2021: $14.67 · 2022: $2,868 · 2023: $386 · 2024: $1,296 · 2025: $7,750.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Grant: $5,682 · Food and Beverage: $1,763 · Travel and Lodging: $1,634 · Education: $352.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Grant | $5,681.69 |
| Food and Beverage | $1,763.38 |
| Travel and Lodging | $1,634.34 |
| Education | $352.36 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $8,248.45 | 2022-2025 | Tacticath, Assurity, Mitraclip |
| Biosense Webster, INC. | $2,610.19 | 2025 | Carto 3, Qdot Micro |
| Abiomed | $693.52 | 2022-2025 | Impella |
| Cardiva Medical, INC. | $213.43 | 2022-2025 | Cardiva Vascade Mvp Xl Vvcs 10-12f |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $193.48 | 2022-2025 | Lifevest |
| Astrazeneca Pharmaceuticals LP | $189.58 | 2020-2023 | Farxiga, Brilinta |
| Medtronic, INC. | $74.75 | 2025 | |
| Janssen Pharmaceuticals, INC | $62.15 | 2024 | Xarelto |
| Chiesi USA, INC. | $46.85 | 2022-2025 | Kengreal |
| E.R. Squibb & Sons, L.L.C. | $41.52 | 2019-2020 | |
| Atricure, INC. | $38.50 | 2025 | Synergy Ablation System, Atriclip Laa Exclusion System |
| Boehringer Ingelheim Pharmaceuticals, INC. | $24.13 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $23.61 | 2023 | |
| United Therapeutics Corporation | $21.00 | 2023 | Tyvaso |
| Novartis Pharmaceuticals Corporation | $16.46 | 2022 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $14.67 | 2021 | |
| Celgene Corporation | $14.55 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Oneib Khan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.